Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00586898 · ClinicalTrials.gov registry record · Phase 2

Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle

A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 2
Development phase
36
Enrollment target

NCT00586898: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.

NCT00586898 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00586898, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
36 participants
Enrollment target

Study Summary

Objective: To determine the response to rapid hormonal cycling in patients with non-castrate prostate cancer.

Interventions

  • DRUG Bicalutamide
  • DRUG GnRH
  • DRUG Ketoconazole
  • DRUG Testosterone transdermal gel
  • DRUG Estrogen transdermal patch

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2001-07
Est. Completion 2009-03
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

What the Registry Record Tells You About NCT00586898

The ClinicalTrials.gov registry entry for NCT00586898 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which Bicalutamide is the first listed.

NCT00586898 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00586898 about?

NCT00586898 is a clinical study titled "Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle". Objective: To determine the response to rapid hormonal cycling in patients with non-castrate prostate cancer.

What is the current status of trial NCT00586898?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2001-07. Estimated completion is 2009-03.

What interventions are being tested in trial NCT00586898?

The interventions under investigation include: Bicalutamide (DRUG), GnRH (DRUG), Ketoconazole (DRUG), Testosterone transdermal gel (DRUG), Estrogen transdermal patch (DRUG).

Who is sponsoring clinical trial NCT00586898?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.